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Abstract: B12 antivitamins are important and robust tools for
investigating the biological roles of vitamin B12. Here, the
potential antivitamin B12 2,4-difluorophenylethynylcobalamin
(F2PhEtyCbl) was prepared, and its 3D structure was studied
in solution and in the crystal. Chemically inert F2PhEtyCbl
resisted thermolysis of its Co@C bond at 100 8C, was stable in
bright daylight, and also remained intact upon prolonged
storage in aqueous solution at room temperature. It binds to the
human B12-processing enzyme CblC with high affinity (KD=
130 nm) in the presence of the cosubstrate glutathione (GSH).
F2PhEtyCbl withstood tailoring by CblC, and it also stabilized
the ternary complex with GSH. The crystal structure of this
inactivated assembly provides first insight into the binding
interactions between an antivitamin B12 and CblC, as well as
into the organization of GSH and a base-off cobalamin in the
active site of this enzyme.
Vitamin B12 (cyanocobalamin, CNCbl) and other cobalamins
(Cbls) are indispensable for the mammalian metabolism[1] on
account of the essential cofactor activities of coenzyme B12
(AdoCbl) and methylcobalamin (MeCbl).[2] To provide
mammalian cells with AdoCbl and MeCbl, natural Cbls are
first transformed into cob(II)alamin (CblII) by the Cbl-
processing chaperone CblC (also named MMACHC, for
methylmalonic aciduria type C and homocystinuria).[3] CblC
binds Cbls base-off and removes their axial Cob ligand
[3c,4] to
furnish CblII, the relevant biosynthetic precursor of AdoCbl
and MeCbl.[3c] Cbls that are transported into cells, but are not
deligated there by CblC, remain metabolically inert and have
been classified as B12 antivitamins.
[5] Such inert vitamin B12
derivatives induce symptoms of B12 deficiency in laboratory
animals,[6] as does a dysfunctional CblC in humans.[3b]
To clarify still puzzling roles of Cbls in humans,[1, 7] B12
deficiency is studied in laboratory animals. The application of
B12 antivitamins
[5, 8] is a rather animal-friendly means in such
studies.[6, 9] Indeed, the antivitamin B12 4-ethylphenylcobala-
min (1, EtPhCbl) induced functional B12 deficiency in
mice.[6, 10] Unfortunately, 1 is susceptible to light-induced
cleavage of its Co@C bond, which uncages its locked B12
activity.[10] Herein, we report the preparation of 2-(2,4-
difluorophenyl)ethynylcobalamin (3, F2PhEtyCbl; Figure 1),
an analogue of the earlier studied light-stable 2-phenylethy-
nylcobalamin (2, PhEtyCbl), which was made more resistant
towards hydrolysis by two fluorine substituents.[11, 12] We also
investigated the interactions of 2 and 3 with the human B12-
processing enzyme CblC, and describe the crystal structure of
the ternary complex of CblC with glutathione (GSH) and 3,
providing unprecedented insight into a holo-CblC complex
that is rendered inactive by an antivitamin B12.
F2PhEtyCbl (3) was prepared in 58% yield by reduction
of aquocob(III)alamin (H2OCbl) with triethylammonium
formate in the presence of 2-(2,4-difluorophenyl)ethynyl
iodide, a method developed for the synthesis of PhEtyCbl
(2).[11a] The reaction probably follows a radical process
initiated by in situ generated CblII, as proposed for the
synthesis of 2.[11a] The UV/Vis spectrum of 3 (Figure 2) is
similar to that of PhEtyCbl (2),[11] but differs significantly
from the spectra of the organometallic B12 cofactors AdoCbl
and MeCbl.[13] In neutral aqueous solution, F2PhEtyCbl (3)
exists in the base-on form, and a strong acid is needed to
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remove the 5,6-dimethylbenzimidazole (DMB) base by pro-
tonation to give 3-H+. The formation of base-off 3-H+ is
accompanied by characteristic hypsochromic shifts of the UV/
Vis absorption maxima (Figure 2). A pKa value of 0.75 was
determined for 3-H+ (see the Supporting Information, Fig-
ure S11), which corresponds to a [base-on]/[base-off] equilib-
rium of about 105 for 3, indicative of strong stabilization of the
base-on form.
The molecular formula and the basic structure of F2Ph-
EtyCbl (3) were delineated from a MALDI-TOF mass
spectrum, an IR spectrum (band of the C/C bond at n˜=
2130.5 cm@1; see Figure S2) and detailed 1H NMR and
13C NMR studies of a solution of 3 in CD3OD (Figure S3).
Orthorhombic crystals of 3 (space group P212121) were grown
from aqueous acetone. The crystal structure of 3 shows a base-
on Cbl with the 2,4-difluorophenylethynyl ligand at the top
(Figures 2, S5, and S6 and Table S1). The geometries and
bond lengths of the inner coordination spheres of the cobalt
centers of 3 and PhEtyCbl (2)[11] are similar. As in 2[11] and in
CNCbl,[14, 15] the axial bonds of 3 are short (Co–C1L
1.877(7)c, Co–N3N 2.071(5)c). Likewise, the ethynyl
group of 3 exhibits a short (1.206(9)c) and nearly linear
C1L/C2L triple bond, with Co-C1L-C2L and C1L-C2L-CL3
bond angles of 170.5(5)8 and 176.1(7)8, respectively. The
plane of the 2,4-difluorophenyl group is nearly parallel to that
of the DMB base, twisted by only 23.1(3)8.
When a solution of F2PhEtyCbl (3) in DMSO was heated
to 100 8C for 24 h, UV/Vis spectroscopy and HPLC analysis
(Figure S7) indicated complete retention of the Co@C bond.
As reported earlier for ethynyl-Cbl[14] and 2,[11,12] solutions of
3 were stable in sunlight (Figure S8). In aqueous solution, 3
underwent slow pH-dependent hydrolysis to H2OCbl. At
pH 2, 3 hydrolyzed with pseudo-first-order kinetics and with
a half-life of about 20 h at room temperature. The roughly
first-order dependence on the H3O
+ concentration from pH 0
to pH 4 (Figures S9 and S10) allowed the hydrolysis-based
half-life of 3 at pH 7 to be estimated as about 107 h. Hence, 3
can be considered as being stable under physiological
conditions.
The binding of F2PhEtyCbl (3) or PhEtyCbl (2) to CblC
was accompanied by blue shifts of the UV/Vis absorptions, as
observed with MeCbl[16] and EtPhCbl.[10] The conversion of
base-on 3 (or 2) into the corresponding base-off form was
slow, as revealed by the UV/Vis spectroscopic changes upon
binding (Figures 3 and S12). Addition of the cosubstrate
glutathione (GSH) caused further hypsochromic shifts of the
maxima. In the presence of GSH, the binding of 3 (or 2) to
CblC was accompanied by a complete switch to the base-off
form, suggesting that GSH binding plays a structuring role in
holo-CblC (Figures 3 and S13). Accommodation of the large
organometallic moiety of 3 in CblC was consistent with
expectations based on the crystal structure of CblC with
bound MeCbl.[17] Isothermal calorimetry (ITC) revealed
a high binding affinity of alkynyl-Cbl 3 to human CblC
Figure 1. Left: General structural formula of important Cbls: vita-
min B12 (L=CN, cyanocob(III)alamin, CNCbl), coenzyme B12 (L=
5’-adenosyl: 5’-deoxyadenosylcob(III)alamin, AdoCbl), methylcob-
(III)alamin (L=methyl: MeCbl), cob(II)alamin (L=e@ : CblII),
4-ethylphenylcob(III)alamin (1; L=4-ethylphenyl: EtPhCbl), and
aquocob(III)alamin (L=H2O
+: H2OCbl). Right: Structural formula of
2-phenylethynylcobalamin (2, PhEtyCbl, X=H) and 2-(2,4-difluorophe-
nyl)ethynylcobalamin (3, F2PhEtyCbl, X=F).
Figure 2. Top: UV/Vis spectra of an aqueous solution of F2PhEtyCbl
(3, c=55 mm) in H2O (black trace) and immediately after acidification
with HClO4 (to 1m) to give base-off H-F2PhEtyCbl
+ (3-H+, red trace).
Bottom: Model of the crystal structure of 3. N blue, O red, P orange,
Co pink, F green. See the Supporting Information for details and
a model of 3 in stereoprojection. Thermal ellipsoids set at 30%
probability.
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(KD= 129: 13 nm) in the presence of GSH, which is about
four times lower than that for 2 (KD= 30: 5.6 nm ; Figures 3
and S15). Incubation of 17–20 mm solutions of 2 or 3 and
10 mm of GSH together with 50 mm CblC at 20 8C for 12 h did
not lead to detectable degradation of either alkynyl-Cbl
(Figure S14). Hence, in contrast to MeCbl, which is rapidly
demethylated by CblC and GSH (kobs= 0.6 min
@1),[10] 2 and 3
were not modified by this universal B12 “tinkerer” (kobs< 3X
10@7 s@1).
The stable ternary complex of alkynyl-Cbl 3, GSH, and
CblC was crystallized by the vapor diffusion method. Crystals
grew in the P6122 space group with one monomer in the
asymmetric unit (Table S2). The structure was solved to 2.5c
resolution (Figures 4 and S16) by molecular replacement by
using a previous structure of CblC as a search model (PDB
No. 3SC0),[17] but omitting the MeCbl cofactor, loops, and
areas with high B-factors. Clear electron density could be
assigned to the Cbl and GSH ligands, which were then
modeled and subsequently refined. Antivitamin 3 was bound
in a base-off form. In this structure (with 3 and GSH bound to
CblC) and in the one with MeCbl bound to CblC,[17] the
position and interactions of the DMB base were not
distinguishable. Likewise, the a and g acetamide side chains
at rings A and D, as well as the b propionamide, are tightly
hydrogen-bonded to the protein part and are found in
identical positions in both crystal structures. Among the
distinct differences, the d and e propionamide and the
c acetamide side chains at rings B and C adopt unique
arrangements in the structure of CblC bound to F2PhEtyCbl
and GSH (Figures 4 and 5). However, they are not as close to
each other and to the Co atom (with Co····N45, Co···N52, and
N45···N52 distances of 4.2, 5.1, and 4.3 c, respectively), as in
MeCbl bound to CblC,[17] thus providing better access to the
lower axial position. In MeCbl bound to CblC, the d and
e propionamide side chains approach each other, and the
Co center is even closer (with Co···N45, Co···N52, and
N45···N52 distances of 4.1, 4.0, and 3.0 c, respectively).
Such striking “tucked-in” structures appear to be a hallmark
of Cbls bound to CblC[17, 18] that is crucial for activation of the
bound corrin for conversion by reductive dealkylation.[3c,4]
Remarkably, in the CblC ternary complex with GSH, the
hydrogen-bonding network between the corrin ring of 3 and
its surrounding protein milieu is largely similar to that of the
binary complexes of CblC with MeCbl[17] and AdoCbl.[18]
Distinct electron density was observed in the vicinity of
the Co atom where a b-axial ligand would be expected
(Figure S17). However, we could not discern an ethynyl
Figure 3. Biochemical studies with CblC, F2PhEtyCbl (3), and GSH.
Top left: Time-dependent UV/Vis spectra for the binding of 3 to CblC.
The original spectrum of 3 is shown in red, the final spectrum after
60 min in black. Bottom left: Spectral changes upon subsequent
binding of GSH. The initial and final spectra are shown in gray and
black, respectively. Right: ITC data for a representative titration of CblC
with 3 in the presence of GSH (10 mm CblC, 200 mm 3, 1 mm GSH).
The binding isotherm (lower panel) was fitted to a model with one
binding site (see the Supporting Information for details).
Figure 4. A) Two views of the structure of GSH and F2PhEtyCbl (3)
bound to CblC (light blue) shown as a cartoon. GSH (yellow) and 3
(dark red) ligands are shown as sticks. B) Two corresponding close-up
views of this ternary complex.
Figure 5. Structural comparison of CblC with bound MeCbl (yellow)
and the ternary complex of CblC with GSH and F2PhEtyCbl (blue). On
the left, the environment of the upper axial Co position in the vicinity
of the GSH ligand is presented. On the right, the environment of the
lower axial Co position is shown. Blue and yellow dotted lines
represent selected distances in the GSH- and F2PhEtyCbl-bound and
MeCbl-bound CblC structures, respectively. Note the arrangement of
the “tucked-in” d and e propionamide side chains.
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carbon atom directly bound to the Co center from the
electron density clearly associated with the F2PhEty group.
Based on a calculated unbiased composite omit map, the 2,4-
difluorophenyl ring was observed in a different position
compared to the free form of F2PhEtyCbl (3) and farther
away from the cobalt atom (Figure 4). The planes of the
phenyl rings in free 3 and in its CblC-bound form were
roughly perpendicular with respect to each other. Moreover,
the axis of the aromatic ring no longer pointed to a Co dz2
orbital. Hence, the 2,4-difluorophenylethynyl group, as it best
fits the experimental electron density, is too far away from the
Co center to be coordinated to it. This model gives a distance
of 3.4c between the CoII center of Cbl and C1L of the
F2PhEty fragment (see Figure 4). Therefore, we posit that the
intense synchrotron radiation used during data collection has
led to cleavage of the Co@C bond, possibly in a reductive
process,[18–20] furnishing (base-off) CblII and a weakly bound
F2PhEty anion.
The electron density clearly correlating with GSH allowed
for a first characterization of its protein environment in CblC
and its location with respect to the bound Cbl (Figures 6A
and S18). An extended network of protein–GSH interactions
anchored this ligand to its binding pocket, namely a combi-
nation of 1) multiple hydrogen-bond interactions with all
three peptide moieties (Glu, Cys, Gly) of GSH and 2)
hydrophobic stacking interactions between the glycine moiety
and protein residues (F223, Y224, and A159). Most of the
GSH ligand is enclosed by the protein and the bound Cbl,
with 70% of the total GSH surface area covered by the
protein and 20% covered by Cbl. In fact, the weakly bound
F2PhEty group packs tightly against GSH, and SGSH is near
the aromatic ring of the F2PhEty fragment, with distances
varying from 4.2 to 5.1c. However, the neighboring CH2
group of GSH is found at distances of 3.9 to 4.0c from the
F2PhEty ring, which is indicative of CH–p contacts. In
contrast, in a model of the protein with bound intact 3, steric
clashes with the GSH ligand occur (Figures S19 and S20).
Previous reports based on available structures, sequence
conservation, and biochemical analysis[17,18, 21] suggested and
identified R230, R161, and R206 as putative residues that are
important for GSH binding. Indeed, our structure determi-
nation confirmed the crucial role of these three arginine
residues and identified R161 as the anchor of GSH in the
CblC active site through interactions of its guanidinium group
and the carboxamide group of the cysteine moiety of GSH.
However, Y215, D77, and D80 were now additionally shown
to form hydrogen bonds to GSH, pointing to an induced fit by
the protein that had previously not been predicted. The sulfur
center (SGSH) of GSH, key to the Cbl dealkylation activity of
CblC, is situated in the vicinity of the bound Cbl with a
Co–SGSH distance of 6.3 c. This corresponds to a calculated
distance of 4.9c between the methyl carbon atom in
a superimposed CblC-boundMeCbl and SGSH in our structure.
This positioning of SGSH relative the bound corrin does not
fulfill the geometric constraints of the proposed SN2-type
mechanism of the dealkylation by GSH. Strikingly, the SGSH
group also lacks any close contacts that would facilitate its
deprotonation and increase its nucleophilicity.
The protein fold of the inactive ternary CblC complex
studied herein reveals distinct differences when compared to
the previously described structures of apo-CblC (PDB No.
3SBZ) and MeCbl-bound CblC (MeCbl:CblC, PDB No.
3SC0;[17] Figure 6). The LDE loop is found in a unique
arrangement as a result of the binding of GSH in the ternary
complex. To accommodate its glutamate moiety, the cosub-
strate GSH also promotes a rearrangement of the N-terminal
moiety of the LDE loop, as the well as the C-terminal region
of the preceding helix (HD), including residues 77–80.
Moreover, the terminal helix (HL) in the four-helix cap
region adopts different conformations in the CblC structures
with MeCbl or F2PhEtyCbl (3) bound. However, the HL
helix appears in the same conformation in both the apo- and
F2PhEtyCbl-bound CblC structures, hinting at the dynamic
nature of this helix.
The base-off forms of 2 and 3 bound effectively to CblC in
the presence of glutathione (GSH). However, as also shown
here, inactive ternary complexes were thus obtained that were
incapable of generating CblII. The lack of reactivity of the
antivitamin B12 3 was employed to trap the cosubstrate GSH
in a previously unattainable form of the ternary complex,
providing the first crystal structure of holo-CblC with GSH
and an antivitamin B12 bound at the same time. This study
Figure 6. A) The GSH-binding environment in the ternary complex
with CblC and F2PhEtyCbl (3). GSH and 3 are shown as yellow and
dark red sticks, respectively. Protein residues of the GSH binding
pocket are shown as blue sticks, and hydrogen bonds are represented
by yellow dotted lines. B) Structural superposition of apo (pink),
MeCbl-bound (yellow), and GSH- and F2PhEtyCbl-bound CblC (blue).
MeCbl (yellow), GSH (blue), and F2PhEtyCbl (blue) ligands are
displayed as sticks. The three major structural differences are high-
lighted with arrows.
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pinpointed the specific protein and Cbl contributions in
anchoring GSH, providing a rational structural basis for
future work with mutant proteins. For example, two severe
pathogenic mutations of CblC (R161G and R161Q) can now
be rationalized, based on the key role of R161 in binding
GSH. B12 antivitamins that are more resistant towards X-ray
reduction than 3 in the complex with GSH may help define
the structural basis for the dealkylation activity of CblC more
precisely.
As explored here for a B12-processing enzyme, B12
antivitamins producing inactive enzyme complexes may be
helpful for solving their crystal structures. Future studies are
also required to learn more about the applicability of B12
antivitamins, such as 3. In fact, EtPhCbl (1) not only induced
“functional B12 deficiency” in mice,
[6] but also helped in
eradicating resistant Gram-negative human pathogens.[22]
Studies of B12 antivitamins and related Cbls as anticancer
agents have also raised interest.[5,8, 23] Indeed, 3 is a promising,
light-stable alternative to the antivitamin B12 1,
[6, 10] and might
also be a very versatile biomedical tool. Long-term experi-
ments with animals in close to natural habitats[6] may be
feasible with 3, and will specifically help in expanding our
knowledge of the physiological effects of B12 deficiency, and
in reducing the gap in understanding its downstream patho-
physiological effects in humans.
Experimental Section
See the Supporting Information for materials, instruments,
synthetic procedures, spectral characterization of compounds and
enzyme complexes, biochemical studies, and X-ray crystallography.
CCDC 1530214 (F2PhEtyCbl, 3) contains the supplementary
crystallographic data for this paper. These data can be obtained free
of charge from The Cambridge Crystallographic Data Centre.
Coordinates and structure factors for F2PhEtyCbl:GSH:CblC have
been deposited in the Protein Data Bank as entry 5UOS.
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